Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline
Date Issued
2006-01-01
Author(s)
Banaschewski, Tobias
Coghill, David
Santosh, Paramala
Zuddas, Alessandro
Asherson, Philip
Buitelaar, Jan
Danckaerts, Marina
Döpfner, Manfred
Faraone, Stephen V.
Rothenberger, Aribert
Sergeant, Joseph
Sonuga-Barke, Edmund J. S.
Taylor, Eric
DOI
10.1007/s00787-006-0549-0
Abstract
A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made.
Subjects
